Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
The trial uncovered no safety red flags during its duration, but the limited follow-up and relatively homogenous patient population indicate there is more work to be done
Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, et al
Avoid large variations between weekdays and weekends whenever possible
Phase 2 trial data showed average weight loss of up to 24.2% at 48 weeks, while the newer Phase 3 trial data showed 28.7% average weight loss at 68 weeks on the 12mg dose
Understanding how these medications function is essential for optimising their use, including determining the most appropriate time of day for administration to maximise therapeutic benefit and minimise adverse effects
Some patients may experience gastrointestinal complications like gastroparesis or reflux, and rare risks include pancreatitis or low blood pressure
US$ 25.57
US$ 28.31
US$ 26.25
US$ 20.14
